$UBX
Unity Biotechnology, Inc.

2020 Q3 Form 10-Q Financial Statement

#000156459020050497 Filed on November 04, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q4 2019 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.530M $4.910M $5.690M
YoY Change 14.76% 13.39% 29.61%
% of Gross Profit
Research & Development $18.83M $18.21M $17.78M
YoY Change 5.92% 11.51% 23.86%
% of Gross Profit
Depreciation & Amortization $830.0K $740.0K $640.0K
YoY Change 29.69% 23.33% 14.29%
% of Gross Profit
Operating Expenses $18.83M $23.09M $22.35M
YoY Change -15.76% 1.23% 15.36%
Operating Profit -$24.64M -$23.09M -$22.35M
YoY Change 10.24% 1.24% 15.36%
Interest Expense -$270.0K $630.0K $756.0K
YoY Change -135.71% -41.12% -29.21%
% of Operating Profit
Other Income/Expense, Net -$2.637M $4.440M -$112.0K
YoY Change 2254.46% -2566.67% 180.0%
Pretax Income -$27.55M -$18.03M -$21.71M
YoY Change 26.9% -17.75% 18.31%
Income Tax
% Of Pretax Income
Net Earnings -$27.55M -$18.03M -$21.71M
YoY Change 26.91% -17.75% 18.34%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$5.25 -$3.86 -$5.05
COMMON SHARES
Basic Shares Outstanding 45.94M 43.20M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2019 Q4 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $132.2M $127.5M $113.0M
YoY Change 16.99% -25.48% -36.45%
Cash & Equivalents $48.58M $37.47M $38.21M
Short-Term Investments $83.60M $90.00M $76.20M
Other Short-Term Assets $3.500M $2.000M $2.200M
YoY Change 59.09% 11.11% 10.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $135.7M $129.5M $125.9M
YoY Change 7.78% -25.14% -29.98%
LONG-TERM ASSETS
Property, Plant & Equipment $37.80M $16.64M $5.400M
YoY Change 600.0% 166.69% -14.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $3.000M $7.400M
YoY Change -100.0% 15.63%
Other Assets $1.400M $627.0K $1.647M
YoY Change -15.0% -61.34% 1.42%
Total Long-Term Assets $39.30M $21.73M $15.78M
YoY Change 149.08% 158.43% 5.86%
TOTAL ASSETS
Total Short-Term Assets $135.7M $129.5M $125.9M
Total Long-Term Assets $39.30M $21.73M $15.78M
Total Assets $175.0M $151.2M $141.7M
YoY Change 23.52% -16.63% -27.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.300M $5.185M $4.578M
YoY Change -6.07% 6.97% 74.47%
Accrued Expenses $12.70M $4.995M $4.912M
YoY Change 158.55% 0.1% 6.37%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.90M $17.22M $14.30M
YoY Change 18.18% 3.82% 22.33%
LONG-TERM LIABILITIES
Long-Term Debt $24.31M $0.00 $0.00
YoY Change
Other Long-Term Liabilities $35.60M $13.30M $12.60M
YoY Change 182.54% 29455.56% 19587.5%
Total Long-Term Liabilities $24.31M $0.00 $12.60M
YoY Change 92.96% -100.0% 19587.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.90M $17.22M $14.30M
Total Long-Term Liabilities $24.31M $0.00 $12.60M
Total Liabilities $76.87M $30.51M $26.96M
YoY Change 185.12% 47.54% 77.32%
SHAREHOLDERS EQUITY
Retained Earnings -$319.7M -$245.5M
YoY Change 50.33%
Common Stock $418.0M $366.7M
YoY Change 12.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $98.10M $120.7M $114.7M
YoY Change
Total Liabilities & Shareholders Equity $175.0M $151.2M $141.7M
YoY Change 23.5% -16.63% -27.23%

Cashflow Statement

Concept 2020 Q3 2019 Q4 2019 Q3
OPERATING ACTIVITIES
Net Income -$27.55M -$18.03M -$21.71M
YoY Change 26.91% -17.75% 18.34%
Depreciation, Depletion And Amortization $830.0K $740.0K $640.0K
YoY Change 29.69% 23.33% 14.29%
Cash From Operating Activities -$17.26M -$15.69M -$16.83M
YoY Change 2.55% 22.58% 21.17%
INVESTING ACTIVITIES
Capital Expenditures $90.00K $610.0K $540.0K
YoY Change -83.33% 38.64% 86.21%
Acquisitions
YoY Change
Other Investing Activities -$6.510M -$3.860M $25.62M
YoY Change -125.41% 614.81% 187.22%
Cash From Investing Activities -$6.610M -$4.480M $25.09M
YoY Change -126.35% 352.53% 190.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 32.86M 20.87M 5.410M
YoY Change 507.39% 6856.67% -54200.0%
NET CHANGE
Cash From Operating Activities -17.26M -15.69M -16.83M
Cash From Investing Activities -6.610M -4.480M 25.09M
Cash From Financing Activities 32.86M 20.87M 5.410M
Net Change In Cash 8.990M 700.0K 13.67M
YoY Change -34.24% -105.19% -359.39%
FREE CASH FLOW
Cash From Operating Activities -$17.26M -$15.69M -$16.83M
Capital Expenditures $90.00K $610.0K $540.0K
Free Cash Flow -$17.35M -$16.30M -$17.37M
YoY Change -0.12% 23.11% 22.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y10M24D
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18830000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
35632000
CY2020Q3 us-gaap Liabilities
Liabilities
76870000
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
5000
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
417952000
CY2020Q3 ubx Related Party Promissory Notes For Purchase Of Common Stock
RelatedPartyPromissoryNotesForPurchaseOfCommonStock
210000
CY2020Q3 ubx Change In Fair Value Of Contingent Consideration For License Agreements
ChangeInFairValueOfContingentConsiderationForLicenseAgreements
-718000
CY2020Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2637000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-27552000
CY2019Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
13298000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2020Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
0
CY2020Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
24313000
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2019Q4 us-gaap Liabilities
Liabilities
30514000
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
366695000
CY2019Q4 ubx Related Party Promissory Notes For Purchase Of Common Stock
RelatedPartyPromissoryNotesForPurchaseOfCommonStock
210000
CY2020Q3 ubx Employee Promissory Notes For Purchase Of Common Stock
EmployeePromissoryNotesForPurchaseOfCommonStock
0
CY2019Q4 ubx Employee Promissory Notes For Purchase Of Common Stock
EmployeePromissoryNotesForPurchaseOfCommonStock
418000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17777000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54218000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
52750000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6530000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5692000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18803000
CY2019Q3 ubx Change In Fair Value Of Contingent Consideration For License Agreements
ChangeInFairValueOfContingentConsiderationForLicenseAgreements
-1115000
us-gaap Operating Expenses
OperatingExpenses
66562000
us-gaap Operating Income Loss
OperatingIncomeLoss
-75147000
us-gaap Operating Income Loss
OperatingIncomeLoss
-66562000
CY2019Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
756000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1093000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2663000
CY2020Q3 ubx Interest Expense Non Operating
InterestExpenseNonOperating
499000
CY2019Q3 ubx Interest Expense Non Operating
InterestExpenseNonOperating
0
ubx Interest Expense Non Operating
InterestExpenseNonOperating
499000
ubx Interest Expense Non Operating
InterestExpenseNonOperating
0
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-112000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
296000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-251000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-21710000
us-gaap Net Income Loss
NetIncomeLoss
-64150000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27718000
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
52482200
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.51
us-gaap Net Income Loss
NetIncomeLoss
-74257000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-166000
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-18000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-24000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
190000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21728000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-74281000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-63960000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.52
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.49
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42965945
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49926396
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42584835
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
120707000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
249000
CY2020Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
100000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
283000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-28038000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
105329000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
355000
CY2020Q2 ubx Vesting Of Early Exercised Options
VestingOfEarlyExercisedOptions
132000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4079000
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
385000
CY2020Q2 ubx Repayment Of Promissory Note From Related Party From Purchase Of Common Stock
RepaymentOfPromissoryNoteFromRelatedPartyFromPurchaseOfCommonStock
56000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-141000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-18667000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
112259000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
582000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3742000
CY2020Q3 ubx Issuance Of Common Stock In Settlement Of Contingent Purchase Consideration Milestone
IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone
1098000
CY2020Q3 ubx Repayment Of Promissory Note From Related Party From Purchase Of Common Stock
RepaymentOfPromissoryNoteFromRelatedPartyFromPurchaseOfCommonStock
318000
CY2020Q3 ubx Repayment Of Promissory Note From Employee Through Repurchase Of Early Exercise Shares Value
RepaymentOfPromissoryNoteFromEmployeeThroughRepurchaseOfEarlyExerciseSharesValue
44000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-166000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-27552000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
98101000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
160693000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
300000
CY2019Q1 ubx Vesting Of Early Exercised Options
VestingOfEarlyExercisedOptions
207000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1997000
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2059000
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
114000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
146603000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
494000
CY2019Q2 ubx Vesting Of Early Exercised Options
VestingOfEarlyExercisedOptions
218000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1944000
CY2019Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
405000
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
965000
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
94000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-23673000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.62
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
127050000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
25000
CY2019Q3 ubx Vesting Of Early Exercised Options
VestingOfEarlyExercisedOptions
149000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3823000
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-18000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-21710000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
114717000
us-gaap Net Income Loss
NetIncomeLoss
-74257000
us-gaap Net Income Loss
NetIncomeLoss
-64150000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2638000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1918000
ubx Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
123000
ubx Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
0
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-47000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1035000
us-gaap Share Based Compensation
ShareBasedCompensation
11113000
us-gaap Share Based Compensation
ShareBasedCompensation
7764000
ubx Common Stock Issued To Third Party
CommonStockIssuedToThirdParty
0
ubx Common Stock Issued To Third Party
CommonStockIssuedToThirdParty
965000
ubx Non Cash Rent Expense
NonCashRentExpense
-586000
ubx Non Cash Rent Expense
NonCashRentExpense
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
2159000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
502000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
0
ubx Accretion Of Tenant Improvement Allowance
AccretionOfTenantImprovementAllowance
0
ubx Accretion Of Tenant Improvement Allowance
AccretionOfTenantImprovementAllowance
873000
ubx Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
-33000
ubx Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
-1327000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1477000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
419000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-625000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
25000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-966000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-331000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-142000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-119000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-361000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-502000
ubx Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
0
ubx Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
1404000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-61619000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-56730000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
92966000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
90158000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
96795000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
163560000
ubx Sale Of Strategic Investments
SaleOfStrategicInvestments
6009000
ubx Sale Of Strategic Investments
SaleOfStrategicInvestments
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
471000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
977000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9367000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
72425000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
37270000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5398000
ubx Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
385000
ubx Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
405000
ubx Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options Net Of Repurchase Payments
ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptionsNetOfRepurchasePayments
1186000
ubx Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options Net Of Repurchase Payments
ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptionsNetOfRepurchasePayments
819000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
24550000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
374000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38214000
ubx Issuance Of Common Stock In Settlement Of Contingent Purchase Consideration Milestone
IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone
1098000
ubx Issuance Of Common Stock In Settlement Of Contingent Purchase Consideration Milestone
IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone
2059000
ubx Issuance Of Shares In Settlement Of Share Based Liability
IssuanceOfSharesInSettlementOfShareBasedLiability
100000
ubx Issuance Of Shares In Settlement Of Share Based Liability
IssuanceOfSharesInSettlementOfShareBasedLiability
0
ubx Lessor Funded Lease Incentives Included In Tenant Improvement Receivable
LessorFundedLeaseIncentivesIncludedInTenantImprovementReceivable
0
ubx Lessor Funded Lease Incentives Included In Tenant Improvement Receivable
LessorFundedLeaseIncentivesIncludedInTenantImprovementReceivable
10650000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
360000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
45000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
52000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
63360000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6570000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11108000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
22265000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-319700000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-245500000
us-gaap Net Income Loss
NetIncomeLoss
-74300000
us-gaap Net Income Loss
NetIncomeLoss
-64200000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-61600000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-56700000
CY2020Q3 ubx Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
132200000
us-gaap Impairment Of Leasehold
ImpairmentOfLeasehold
2200000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed financial statements have been prepared in accordance with GAAP, which requires management to make estimates and assumptions that affect the amounts and disclosures reported in the condensed financial statements and accompanying notes. The Company bases its estimates on historical experience and market-specific or other relevant assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s condensed balance sheets and the amount of expenses and income reported for each of the periods presented are affected by estimates and assumptions, which are used for, but are not limited to, determining the fair value of assets and liabilities, contingent consideration liability and stock-based compensation. Actual results could differ from such estimates or assumptions.</p>
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48581000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37473000
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1446000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1446000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50027000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38919000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Risk </p> <p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash and marketable securities. Substantially all of the Company’s cash and cash equivalents and restricted cash is deposited in accounts with financial institutions that management believes are of high credit quality. Such deposits have and will continue to exceed federally insured limits. The Company maintains its cash with accredited financial institutions and accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses on its cash deposits. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s investment policy limits investments in marketable securities to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents, restricted cash and marketable securities and issuers of marketable securities to the extent recorded on the balance sheets. As of September 30, 2020, the Company had no off-balance sheet concentrations of credit risk. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company depends on third-party suppliers for key raw materials used in its manufacturing processes and is subject to certain risks related to the loss of these third-party suppliers or their inability to supply the Company with adequate raw materials. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the World Health Organization declared the global novel coronavirus (“COVID-19”) outbreak a pandemic. To date, the Company’s operations have not been significantly impacted by the COVID-19 pandemic. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 pandemic will have on its financial condition and results of operations, including ongoing and planned clinical studies. The impact of the COVID-19 pandemic on the financial performance of the Company will depend on future developments, including the duration and spread of the COVID-19 pandemic and related governmental advisories and restrictions. These developments and the impact of COVID-19 on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, the Company’s business, financial condition, results of operations and prospects may be adversely affected.  </p>
us-gaap Concentration Risk Credit Risk Financial Instruments Off Balance Sheet Risk
ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk
As of September 30, 2020, the Company had no off-balance sheet concentrations of credit risk.
CY2020Q3 ubx Concentration Risk Credit Risk Off Balance Sheet Risk
ConcentrationRiskCreditRiskOffBalanceSheetRisk
0
CY2020Q3 us-gaap Lessee Finance Lease Term Of Contract1
LesseeFinanceLeaseTermOfContract1
P3Y
CY2020Q3 ubx Cash Proceeds From Sale Of Investment
CashProceedsFromSaleOfInvestment
6000000.0
CY2020Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
2200000
CY2019 us-gaap Equity Method Investment Sold Carrying Amount
EquityMethodInvestmentSoldCarryingAmount
1000000.0
CY2019Q3 us-gaap Equity Method Investment Sold Carrying Amount
EquityMethodInvestmentSoldCarryingAmount
1000000.0
CY2020Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
122398000
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
66000
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
122464000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
124368000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
92000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
124459000
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
ubx Compound Library And Option Agreement Execution Month And Year
CompoundLibraryAndOptionAgreementExecutionMonthAndYear
2016-02
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1140000
us-gaap Operating Lease Cost
OperatingLeaseCost
3584000
CY2020Q3 us-gaap Variable Lease Cost
VariableLeaseCost
363000
us-gaap Variable Lease Cost
VariableLeaseCost
1004000
ubx Impairment Of Operating Lease Right Of Use Asset
ImpairmentOfOperatingLeaseRightOfUseAsset
1157000
CY2020Q3 us-gaap Lease Cost
LeaseCost
1503000
us-gaap Lease Cost
LeaseCost
5745000
us-gaap Operating Lease Expense
OperatingLeaseExpense
3000000.0
us-gaap Operating Lease Payments
OperatingLeasePayments
4172000
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.058
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1626000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6653000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6283000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4810000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
4964000
CY2020Q3 ubx Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
27302000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
51638000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
11591000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
40047000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4415000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
35632000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
3838000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
12272000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
8890000
CY2020Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
25000000
CY2020Q3 ubx Term Fee Due At Maturity Amount
TermFeeDueAtMaturityAmount
1562000
CY2020Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
26562000
CY2020Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
2249000
CY2020Q3 us-gaap Long Term Debt
LongTermDebt
24313000
CY2019Q2 ubx Sale Of Equity Financing Authorized Amount
SaleOfEquityFinancingAuthorizedAmount
250000000.0
CY2020Q3 us-gaap Severance Costs1
SeveranceCosts1
1800000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6906898
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3949756
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.46
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
215037
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.91
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
1428825
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
8.11
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9212792
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.13
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
200000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
3200000
ubx Share Based Compensation Arrangement By Share Based Payment Number Of Shares Issued In Settlement Of Liability Award
ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesIssuedInSettlementOfLiabilityAward
13550
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3692000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3823000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11113000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7764000
ubx Share Based Compensation Arrangement By Share Based Payment Expense Related To Liability Award
ShareBasedCompensationArrangementByShareBasedPaymentExpenseRelatedToLiabilityAward
100000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-27552000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-21710000
us-gaap Net Income Loss
NetIncomeLoss
-74257000
us-gaap Net Income Loss
NetIncomeLoss
-64150000
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
52482200
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42965945
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49926396
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42584835
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.52
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.49
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.51
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13033490
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7130057

Files In Submission

Name View Source Status
0001564590-20-050497-index-headers.html Edgar Link pending
0001564590-20-050497-index.html Edgar Link pending
0001564590-20-050497.txt Edgar Link pending
0001564590-20-050497-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ubx-10q_20200930.htm Edgar Link pending
ubx-10q_20200930_htm.xml Edgar Link completed
ubx-20200930.xsd Edgar Link pending
ubx-20200930_cal.xml Edgar Link unprocessable
ubx-20200930_def.xml Edgar Link unprocessable
ubx-20200930_lab.xml Edgar Link unprocessable
ubx-20200930_pre.xml Edgar Link unprocessable
ubx-ex102_78.htm Edgar Link pending
ubx-ex103_34.htm Edgar Link pending
ubx-ex311_6.htm Edgar Link pending
ubx-ex312_9.htm Edgar Link pending
ubx-ex321_8.htm Edgar Link pending